BERLIN, Germany, 05 September 2023 – Life Molecular Imaging (LMI) is pleased to announce today that new research results on its approved and investigational positron emission tomography (PET) tracers will be presented at the 36th Annual Congress of the European Association of Nuclear Medicine on September 9-13, 2023 in Vienna, Austria.
The contributions cover ten (10) presentations demonstrating the utility of its approved compound NeuraCeq® (florbetaben 18F) and four (4) presentations supporting the potential of its investigational tau tracer 18F-PI-2620.
“We are very impressed by the convincing data that research groups around the world have collected over the last year” said Dr. Andrew Stephens, MD, PhD, CMO of Life Molecular Imaging. “PET Imaging is broadly expanding, discovering new insights into pathophysiology and providing critical biomarker data for diagnosing and monitoring patients.”
Meet the LMI team in Hall X4 – Level 0 at booth #406 at EANM in Vienna.
Selected datasets involving LMI compounds presented at the EANM conference include the following presentations:
Amyloid-PET Neuroimaging with NeuraCeq® (florbetaben 18F)
|
Format |
Schedule |
Title |
Authors |
Details |
1 |
Oral |
Sunday, September 10, 2023, 8:00 AM – 9:30 AM |
A pilot study comparing myelin measurements from [18F]-Florbetaben PET and quantitative T1 map imaging in multiple sclerosis (MS) |
L. Sofia, M. Donegani, A. Donniaquio, A. Chincarini, L.Roccatagliata, M. Pardini, R. Gianeri, F. Sensi, F. D’Amico, T.Di Raimondo, C. Bagnara, M. Riondato, G. Novi, A. Laroni, A. Murialdo, G. Ribizzi, A. Uccelli, M. Inglese, S. Morbelli |
OP-051 Hall F1 |
2 |
Oral |
Sunday, September 10, 2023, 9:45 AM – 11:15 AM |
Quantification of baseline amyloid load in individuals with subjective cognitive decline can identify future risk of amyloid accumulation |
G. Kolinger, M. Marquié, O. Sotolongo-Grau, N. Roé-Vellvé, E.Pérez-Martínez, N. Koglin, A. Stephens, J. Tartari, Á. Sanabria, A. García-Sánchez, L. Tárraga, A. Ruiz, S. Bullich, M. Boada |
OP-103 Hall F1 |
3 |
Poster |
Monday, September 11, 2023, 8:00 AM – 9:30 AM |
Quantification of amyloid load from [18F]florbetaben PET scans agrees with histopathology, visual read, and clinical progression |
G. Kolinger, L. Tiraboschi, F. Padovano, D. Braca, M. Spitilli, G.Lucidi Pressanti, S. Bullich, R. Mazza |
EPS-085 Hall G2 |
4 |
Poster |
Monday, September 11, 2023, 4:45 PM – 6:15 PM |
Early-phase [18F]FBB PET vs [18F]FDG PET in atypical dementia: preliminary data from a multicentric study (AMY-ITA). |
D. Cecchin, A. Chincarini, S. Mozzetta, C. Gagliani, A. Osele, S.Morbelli, S. Sestini, F. Dore, M. Dottorini, L. Ruffini, G. Trifirò, M. Farsad, L. Turk, A. Cagnin |
EPS-149 Hall G2 |
5 |
Poster |
Tuesday, September 12, 2023, 8:00 AM – 9:30 AM |
Development of deep learning model for generalized utilization to restore short-scanning PET images using three radiopharmaceuticals |
Y. Jeong, S. Cheon, H. Park, K. Jeon |
EPS-168 Hall G2 |
6 |
Poster |
ePoster |
Applicability of early phase imaging with 18F-PI-2620 and 18F-Florbetaben in mouse models with Tau and Amyloid pathology |
A. Englert, L. Slemann, S. Hummel, L. Hörmann, L. Kunze, C.Palleis, K. Wind-Mark, S. Lindner, P. Bartenstein, S. Ziegler, N.Albert, J. Levin, M. Brendel, J. Gnörich |
EP-0024 EP-02, e-Poster Area |
7 |
Poster |
ePoster |
Florbetaben PET quantification strongly agrees with histopathological confirmation of amyloid-beta load and visual reads. |
S. Bullich, J. Koikkalainen, A. Jovalekic, N. Roé-Vellvé, G. D. Kolinger, N. Koglin, A. W. Stephens, L. Thurfjell |
EP-0678 EP-46, e-Poster Area |
8 |
Poster |
ePoster |
Centiloid Calibration of a Commercial Amyloid Quantitation Software for different Fluorine-18 Radiotracers |
R. Fahmi |
EP-0683 EP-46, e-Poster Area |
9 |
Poster |
ePoster |
Assessment of a new PET event-by-event image-based motion correction for brain imaging in amyloid and epilepsy on a multimodality PET-MR scanner |
J. Anton Rodriguez, K. Herholz, C. Oldfield, M. G. Spangler-Bickell, T. W. Deller, L. M. Parkes, J. C. Matthews |
EP-0720 EP-48, e-Poster Area |
10 |
Poster |
ePoster |
Description amyloid PET (18F-Florbetaben) imaging protocol in patients with suspected Alzheimer’s disease |
M. Caballero Vivancos, M. Pérez Ávila, F. González Asid, E. Córdoba Cañete, R. Sánchez Sánchez |
EP-1032 EP-65, e-Poster area |
Tau-PET Neuroimaging with 18F-PI-2620
|
Format |
Schedule |
Title |
Authors |
Details |
11 |
Oral |
Sunday, September 10, 2023, 9:45 AM – 11:15 AM |
[18F]PI-2620 PET Imaging of 3R Pick Tau in Frontotemporal Lobar Degeneration – A Multi-Centre Study |
H. Barthel, M. Brendel, V. Villemagne, K. Marek, T. van Eimeren, M. Rullmann, M. Schroeter, D. Saur, M. Patt, J.Classen, J. Seibyl, A. Drzezga, O. Sabri |
OP-108 Hall F1 |
12 |
Poster |
Monday, September 11, 2023, 4:45 PM – 6:15 PM |
Improving the quantification of tau pathology in Alzheimer’s Disease: A data-driven analysis using 18FPI2620 PET. |
G. Bischof, M. Kanekiyo, M. Irrizari, A. Stephens, T. van Eimeren, A. Drzezga |
EPS-147 Hall G2 |
13 |
Poster |
Monday, September 11, 2023, 4:45 PM – 6:15 PM |
Single Tracer ATN Assessment With Dynamic 18F-PI-2620 Recordings |
J. Gnörich, M. Zaganjori, M. Groß, M. Scheifele, A. Bronte, R. Perneczky, K. Bürger, J. Levin, O. Sabri, P. Bartenstein, H. Barthel, N. Franzmeier, M. Brendel |
EPS-148 Hall G2 |
14 |
Poster |
ePoster |
Applicability of early phase imaging with 18F-PI-2620 and 18F-Florbetaben in mouse models with Tau and Amyloid pathology |
A. Englert, L. Slemann, S. Hummel, L. Hörmann, L. Kunze, C.Palleis, K. Wind-Mark, S. Lindner, P. Bartenstein, S. Ziegler, N.Albert, J. Levin, M. Brendel, J. Gnörich |
EP-0024 EP-02, e-Poster Area |
About Neuraceq (florbetaben 18F)
Indication
Neuraceq® is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation.
A negative Neuraceq® scan indicates sparse to no plaques, which is not consistent with a diagnosis of AD. Neuraceq is for diagnostic use only.
Limitations of Use
- A positive Neuraceq® scan does not independently establish a diagnosis of AD or other cognitive disorder, since neuritic plaque deposition in grey matter may be present in asymptomatic elderly and some neurodegenerative dementias (AD, Lewy body dementia, Parkinson’s disease dementia).
- The efficacy of florbetaben (18F) for predicting development of AD or monitoring response to therapy has not been established.
- Some scans may be difficult to interpret due to image noise, atrophy with a thinned cortical ribbon, or image blurs, which could lead to interpretation errors.
- Increased uptake has been identified in extracerebral structures such as face, scalp and bone in some cases. Residual activity in the midsagittal sinus can be sometimes observed.
Important Safety Information
Interpretation of Neuraceq images
Neuraceq images should only be interpreted by readers trained in the interpretation of PET images with florbetaben (18F). A negative scan indicates sparse or no density of cortical β-amyloid plaques. A positive scan indicates moderate to frequent density. Image interpretation errors in the estimation of brain β-amyloid neuritic plaque density, including false negatives and false positives, have been observed.
Radiation Risk
Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. As the effective dose is about 5.8 mSv when the maximum recommended activity of 300 MBq of florbetaben (18F) is administered, these adverse reactions are expected to occur with a low probability.
Common Adverse Reactions
The overall safety profile of Neuraceq is based on data from 1,295 administrations of Neuraceq to 1,077 subjects and 12 subjects who received vehicle. Repeat dosing in yearly intervals showed that there was no difference in safety profile after first, second or third dosing. Common adverse reactions include injection site pain and injection/ application site erythema.
About [18F]PI-2620
Tau deposits, in conjunction with beta-amyloid plaques, represent the other pathological hallmark of Alzheimer’s disease, with tau deposits further playing an important role in other neurodegenerative diseases. [18F]PI-2620 is binding to 3R/4R and 4R tau deposits and is a next generation 18F-labeled investigational PET tracer with favourable properties and imaging characteristics. It was discovered in a research collaboration between Life Molecular Imaging and AC Immune, a Swiss-based clinical stage biopharmaceutical company. Life Molecular Imaging has the exclusive, world-wide license for research, development and commercialization of tau PET tracers generated within the discovery program.
About Life Molecular Imaging (LMI)
Life Molecular Imaging was formed in 2012 with the acquisition of the molecular imaging research and development portfolio of Bayer Pharma AG. It is now part of the Alliance Medical Group (a member of the Life Healthcare Group) offering an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. By developing novel PET tracers for molecular imaging, LMI is focusing on a key field of modern medicine. The organization strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. Please visit https://life-mi.com.
About Life Healthcare Group
Life Healthcare is a global people-centered, diversified healthcare organization listed on the Johannesburg Stock Exchange. Life Healthcare has over 38 years’ experience in the South African private healthcare sector, and currently operates 66 healthcare facilities in southern Africa. Services include acute hospital care, acute physical rehabilitation, acute mental healthcare, renal dialysis, and wellness, occupational health, primary health and emergency medical services. The Group owns Alliance Medical Group, the leading independent provider of medical imaging services (MRI, CT and PET scans) within Europe, operating internationally across 10 countries. Life Molecular Imaging, a division of Alliance is an integrated pharmaceutical business that includes research and development laboratories, access to a network of cyclotrons and radio-pharmacies and imaging facilities, with Life Radiopharma being Alliance’s distributor of radiopharmaceuticals to diagnose many types of diseases. Visit https://www.lifehealthcare.co.za/